.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Chinese Patent Office
US Department of Justice
AstraZeneca
Queensland Health
Mallinckrodt
Cantor Fitzgerald
Argus Health
Farmers Insurance
Moodys

Generated: June 27, 2017

DrugPatentWatch Database Preview

Selexipag - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for selexipag and what is the scope of selexipag freedom to operate?

Selexipag
is the generic ingredient in one branded drug marketed by Actelion Pharms Ltd and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selexipag has sixty-seven patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for Generic Name: selexipag

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list27
Clinical Trials: see list13
Patent Applications: see list34
Drug Prices:see low prices
DailyMed Link:selexipag at DailyMed

Pharmacology for Ingredient: selexipag

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-001Dec 21, 2015RXYesNo9,284,280► Subscribe ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-006Dec 21, 2015RXYesNo9,173,881► Subscribe ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-007Dec 21, 2015RXYesNo9,173,881► Subscribe ► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-004Dec 21, 2015RXYesNo► Subscribe► Subscribe
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-002Dec 21, 2015RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: selexipag

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,597,331Therapeutic compositions containing macitentan► Subscribe
9,340,516Form-II crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl) acetamide, method for producing the same, and use thereof► Subscribe
8,809,334Therapeutic compositions containing macitentan► Subscribe
9,440,931Form-III crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: selexipag

Country Document Number Estimated Expiration
BrazilPI0209249► Subscribe
China104326991► Subscribe
Russian Federation2011109084► Subscribe
South Korea20120109457► Subscribe
Japan5764061► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SELEXIPAG

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
266Luxembourg► SubscribePRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519
2016000077Germany► SubscribePRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512
0836Netherlands► SubscribePRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
C0042France► SubscribePRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519
2016 00048Denmark► SubscribePRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
QuintilesIMS
McKinsey
Chinese Patent Office
UBS
Farmers Insurance
Medtronic
Healthtrust
US Department of Justice
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot